Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 30;11(3):207. doi: 10.1038/s41419-020-2388-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Better EFS was observed in patients with non-refractory disease compared with patients with refractory disease (a), in patients with blast <5% compared with patients with blast ≥5% (b), in patients with other lymphodepletion regimens compared with patients with Flu + Cy regimen (c), as well as in patients bridged to HSCT compared with patients with CAR-T therapy only (d). Kaplan–Meier curve was used to demonstrate survival profiles, and the log-rank test was used to determine the difference between paired subgroups. P < 0.05 was considered significant. EFS, event-free survival; Flu + Cy, cyclophosphamide plus fludarabine; HSCT, hematopoietic stem-cell transplantation; CAR-T, chimeric antigen-specific T cell.